Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J68D | ISIN: CNE100001M79 | Ticker-Symbol: 08HH
Tradegate
13.05.26 | 08:08
2,070 Euro
+0,39 % +0,008
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,9802,07619:37
1,9812,07519:38

Aktuelle News zur SHANGHAI FOSUN PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:26FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE OF A SUBSIDIARY'S DRUG REGISTRATION APPLICATION2
MoFOSUN PHARMA (02196): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS1
MoFOSUN PHARMA (02196): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS10
MoFOSUN PHARMA (02196): FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE 2026 SECOND CLASS MEETING OF HOLDERS OF H SHARES TO BE HELD ON TUESDAY, 16 JUNE 20261
MoFOSUN PHARMA (02196): FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 16 JUNE 20261
SHANGHAI FOSUN PHARMACEUTICAL Aktie jetzt für 0€ handeln
MoFOSUN PHARMA (02196): NOTICE OF 2026 SECOND H SHAREHOLDERS CLASS MEETING2
MoFOSUN PHARMA (02196): NOTICE OF ANNUAL GENERAL MEETING2
MoFOSUN PHARMA (02196): ANNUAL GENERAL MEETING; REMUNERATION MANAGEMENT SYSTEM FOR DIRECTORS AND SENIOR MANAGEMENT; ENTRUSTED LOANS/BORROWINGS QUOTA; AUTHORISATION ...3
FrFOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL FOR DRUG REGISTRATION OF A SUBSIDIARY2
30.04.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL FOR DRUG REGISTRATION OF A SUBSIDIARY3
30.04.CLSA: FOSUN PHARMA 1Q26 Results Slightly Miss Market Expectations3
28.04.Shanghai Fosun Pharmaceutical (Group) Co Ltd Q1 Income Rises4
28.04.Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution601SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter...
► Artikel lesen
28.04.FOSUN PHARMA (02196): 2026 FIRST QUARTERLY REPORT1
28.04.Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework173Strategic framework established for regional and global licensing, frontier technology incubation, and strategic collaboration in neurodegenerative diseases Joint R&D aligned with...
► Artikel lesen
22.04.M Stanley Rates FOSUN PHARMA as Overweight With TP HKD32, Lifts Rev. Forecast9
21.04.FOSUN PHARMA (02196): NOTIFICATION LETTER TO SHAREHOLDERS - NOTICE OF PUBLICATION OF 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) AND SUSTAINABILITY ...13
21.04.FOSUN PHARMA (02196): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) AND SUSTAINABILITY REPORT3
21.04.FOSUN PHARMA (02196): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 20251
21.04.FOSUN PHARMA (02196): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 20251
Weiter >>
81 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1